Cytoniche

CytoNiche™ is transforming the cell and gene therapy (CGT) industry through its scalable 3D FloTrix™ platform, delivering end-to-end solutions for industrial-scale CGT manufacturing. Our integrated portfolio includes GMP-grade dissolvable microcarriers, serum-free media for mesenchymal stromal/stem cells (MSCs), and a comprehensive suite of GMP-compliant equipment and consumables, supporting the full cell production workflow—from expansion and harvesting to downstream processing and filling. Guided by a vision to lead the next era of cell industrialisation, CytoNiche empowers CGT innovation through intelligent, 3D large-scale cell manufacturing technologies. By significantly reducing production timelines and costs while enhancing scalability, our platform enables the efficient production of billions of high-quality cells, far beyond the limits of traditional 2D systems. Our core products are supported by FDA Master Files and are already being adopted in multiple registered clinical trials, as well as in a commercialised cell therapy product. Designed for flexibility and future readiness, CytoNiche systems support a broad range of adherent-cell applications, including MSCs, exosomes, and next-generation cell-based therapies. By re-engineering the manufacturing footprint—minimising facility size, automating labour-intensive processes, and reducing contamination risk—CytoNiche is accelerating the transition toward sustainable, scalable biomanufacturing. Our mission is to make advanced cell therapies more affordable, accessible, and rapidly deployable, ultimately benefiting patients worldwide.